Related Experiment Video
Updated: Mar 25, 2026
Use of In vivo Imaging to Monitor the Progression of Experimental Mouse Cytomegalovirus Infection in Neonates
Published on: July 6, 2013
[A 5-year retrospective clinical study of perinatal cytomegalovirus infection]
Li-Wei Liu1, Ji-Hong Qian, Tian-Wen Zhu
1Department of Neonatology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China. qianjh668@126.com.
Insights
Perinatal cytomegalovirus (CMV) infection is stable, often affecting multiple organs. Ganciclovir is effective, but pregnancy history and liver involvement impact treatment outcomes in infants.
Area of Science:
- Neonatal infectious diseases
- Virology
- Pediatric pharmacology
Context:
- Perinatal cytomegalovirus (CMV) infection poses a significant threat to infant health.
- Understanding the epidemiology and clinical manifestations of congenital CMV is crucial for timely diagnosis and management.
- Ganciclovir is a primary antiviral agent used in treating severe CMV infections.
Purpose:
- To determine the incidence, clinical features, and treatment outcomes of perinatal CMV infection in hospitalized infants.
- To identify factors influencing the efficacy of ganciclovir treatment in this population.
- To analyze trends in perinatal CMV infection over a five-year period.
Summary:
- A retrospective analysis of 237 infants with perinatal CMV infection (2008-2012) revealed stable incidence and clinical features.
- The most common presentation involved multiple organ systems, particularly hepatitis and pneumonia (43.1%).
- Ganciclovir achieved an 88.3% cure rate in 197 treated infants; however, abnormal pregnancy history and pre-treatment liver involvement were independent risk factors for poorer outcomes.
Impact:
- This study highlights the consistent epidemiological profile of perinatal CMV infection.
- It underscores the significant efficacy of ganciclovir while identifying key risk factors for treatment resistance.
- Findings aid in optimizing therapeutic strategies and risk stratification for infants with perinatal CMV infection.
Objective:
To investigate the incidence, clinical features, and treatment of perinatal cytomegalovirus (CMV) infection, as well as the factors affecting the therapeutic effect of ganciclovir.
Methods:
The clinical data of 237 infants who were hospitalized and diagnosed with perinatal CMV infection from 2008 to 2012 were retrospectively analyzed.
Results:
The clinical features of infants with perinatal CMV infection and the proportion of such infants in all hospitalized infants showed no significant differences across the five years. In most infants, two or more systems were involved, and CMV hepatitis plus CMV pneumonia was most common (43.1%). The results of pathogen detection showed that the percentage of the infants with positive blood CMV-IgM and blood/urine CMV-DNA was 3.8%, while 90.3% of all infants had positive blood CMV-IgM alone and 5.9% had positive blood/urine CMV-DNA alone. A total of 197 infants were treated with ganciclovir, and the cure rate was 88.3%. An abnormal history of pregnancy (OR=6.191, 95% CI: 1.597-24.002) and liver involvement before medication (OR=3.705, 95% CI: 1.537-8.931) were the independent risk factors affecting the therapeutic effect of ganciclovir in infants with perinatal CMV infection.
Conclusions:
The epidemiological characteristics of perinatal CMV infection have remained generally stable for the last 5 years. CMV often involves several organs or systems, especially the liver and lung. Ganciclovir has a significant efficacy in the treatment of perinatal CMV infection, and an abnormal history of pregnancy and liver involvement before medication can increase the risk of ganciclovir resistance in infants with perinatal CMV infection.
More Related Videos
05:51Intracerebroventricular and Intravascular Injection of Viral Particles and Fluorescent Microbeads into the Neonatal Brain
Published on: July 24, 2016
08:08qPCR Is a Sensitive and Rapid Method for Detection of Cytomegaloviral DNA in Formalin-fixed, Paraffin-embedded Biopsy Tissue
Published on: July 9, 2014
